新型免疫细胞疗法B-SYNC CAR-T在小鼠模型中成功消除致命脑肿瘤
Scientists wipe out deadly brain tumors in every mouse tested with new cancer therapy
UCSF的研究团队开发了一种新型B-SYNC CAR-T免疫细胞疗法,可在不引起副作用的情况下有效攻击脑肿瘤。实验结果显示,该疗法在小鼠模型中完全消除了弥漫性中线胶质瘤,并提供了长期保护。研究人员计划在2027年4月开始临床试验。
研究在小鼠模型中展示了B-SYNC CAR-T细胞对难治性脑肿瘤的有效治疗效果,为临床应用提供了希望。
译文尚不完整,完整内容请切换到原文。
Scientists at UC San Francisco have developed a new type of immune cell therapy that activates only after entering the brain, allowing it to attack cancer while remaining inactive elsewhere in the body.
In experiments involving mice, the engineered cells successfully eliminated diffuse midline glioma (DMG), an aggressive childhood brain cancer that spreads into surrounding healthy tissue. The treatment also provided lasting protection. When researchers introduced cancer cells again several weeks later, the immune cells continued fighting and prevented new tumors from developing.
DMG is among the most difficult childhood cancers to treat. It grows into the brainstem, a critical region that regulates breathing, heartbeat, and swallowing. Nearly all children diagnosed with the disease die within a year, and existing treatments have had little success in stopping its progression.
The experimental therapy, called B-SYNC CAR-T, could offer a new way forward. Unlike conventional CAR-T treatments, which have struggled against brain tumors, these modified immune cells are programmed to activate their cancer-fighting machinery specifically within the brain. Researchers suspect this targeted approach makes the cells more effective, although the precise reason remains unclear.
The promising results have prompted scientists to prepare for clinical trials at UCSF Health, potentially beginning as early as April 2027.
"It's been a struggle to make CAR-T cells that overcome DMG without causing unacceptable side effects," said Hideho Okada, MD, PhD, a professor of Neurological Surgery at UCSF and co-corresponding author of the study, published October 28 in Science Translational Medicine. "By limiting B-SYNC's CAR expression to when and where it matters -- in the brain -- we saw consistent, total shutdown of DMG tumors in the lab."
Engineering Smarter CAR-T Cells to Fight Brain Cancer
B-SYNC builds on years of research by Okada and Wendell Lim, PhD, a professor of Cellular and Molecular Pharmacology at UCSF. Their goal has been to develop immune cells that can recognize and destroy brain tumors with greater precision.
CAR-T therapy works by modifying the body's T cells, a type of immune cell, so they carry special receptors called CARs. These receptors recognize proteins on cancer cells and trigger an immune attack. Although CAR-T treatments have shown success against certain cancers, brain tumors have remained particularly difficult to overcome.
In 2021, Okada and Lim reported encouraging laboratory findings with an earlier therapy called E-SYNC, designed to treat glioblastoma, another aggressive form of brain cancer.
E-SYNC uses a molecular sensing system known as synNotch to identify EGFRvIII, a mutated protein found on some glioblastoma cells. When this protein is detected, synNotch directs the immune cell to produce a CAR that recognizes two additional tumor-associated proteins, EphA2 and IL13Rα2. This two-step process proved more effective than conventional CAR-T strategies that rely on a single activation step.
However, the approach had an important limitation. Only about 20% of patients have tumors containing EGFRvIII. Even when the protein is initially present, tumors can lose it as treatment eliminates the cancer cells carrying it. This allows remaining cancer cells to escape detection.
To overcome that problem, the researchers searched for a more dependable signal that could activate the therapy in a wider range of patients.
大脑内部激活的分子开关
科学家们识别出 brevican 这种蛋白质作为潜在的替代品,这种蛋白质在大脑中自然分布。
他们重新设计了 synNotch 系统,使其仅在遇到 brevican 时才会触发 CAR 生产。一旦激活,这些“B-SYNC”CAR-T 细胞就能够搜索携带 EphA2 或 IL13Rα2 的癌细胞,即使这些细胞不携带 EGFRvIII。
这意味着工程化的免疫细胞不再依赖于特定的肿瘤突变来激活。相反,它们使用与大脑本身相关的蛋白质作为开始攻击的信号。
虽然 B-SYNC 初始是为胶质母细胞瘤开发的,但研究人员认识到它也可能适用于 DMG。这两种癌症通常在肿瘤细胞上显示 EphA2 和 IL13Rα2,使其成为相同的治疗方法的潜在目标。
Okada 实验室的博士后研究员 Senthilnath Lakshmanachetty 领导了实验,以调查 B-SYNC 是否能够成功攻击这种致命的儿童癌症。
新型 CAR-T 疗法在小鼠中消除脑肿瘤
研究人员首先通过静脉注射 (IV) 给植入了人类 DMG 细胞的小鼠注射了 B-SYNC CAR-T 细胞。
一些工程化的免疫细胞通过血液循环进入大脑。一旦到达那里,它们就开始生产针对癌细胞的 CAR 受体并攻击肿瘤细胞。
重要的是,这种激活似乎仅发生在预期位置。B-SYNC 细胞在身体的其他部位,包括血液中的循环细胞或脾脏中的细胞,没有产生 CAR 受体。
这“正是我们设计的”,Lakshmanachetty 说。
该团队接下来研究直接将治疗药物送入大脑是否能产生更强的效果。他们使用脑室注射(intracerebroventricular, ICV)的方式给予 B-SYNC,这种方式将细胞引入大脑的充满液体的脑室中。
结果令人瞩目。在两种含有人类DMG肿瘤的小鼠模型中,治疗完全消除了每只小鼠的癌症。相比之下,传统的CAR-T细胞无法控制肿瘤的生长。
这些发现表明,在大脑中特异性激活工程免疫细胞可能克服了早期CAR-T治疗的一些障碍。
免疫细胞在肿瘤消失后仍持续战斗
消除原始肿瘤只是成就的一部分。研究人员还想知道这些工程免疫细胞是否能保持活性并防止癌症复发。
在初次治疗后近七周,他们向已经接受过 B-SYNC 治疗的小鼠再次引入 DMG 细胞。
每只接受治疗的小鼠都拒绝了新的癌细胞,这表明该疗法的保护效果持续了远超初次消除肿瘤的时间。
进一步的观察显示,B-SYNC 细胞在治疗后超过 70 天仍保持功能。
一种可能的解释涉及一种称为T细胞耗竭的问题。当免疫细胞长时间保持激活状态时,它们会逐渐失去有效攻击癌症的能力。通过在细胞到达大脑时才激活CAR,B-SYNC 可能有助于在它们遇到肿瘤细胞时保持其力量。
研究人员认为,这可能是他们的方法比传统CAR-T疗法效果更好的一个重要原因。
"我们没想到 B-SYNC CAR-T 细胞一定会持久存在," Lakshmanachetty 说。"但它们仍然在 70 多天后巡逻寻找癌症——并且仍然非常有效。"
人类临床试验可能在 2027 年 4 月开始
在实验室结果证明具有肿瘤消除和持久免疫活性之后,UCSF 团队现在正致力于将 B-SYNC 进入人体测试。
Okada、Lim 和 Lakshmanachetty 正与 UCSF 癌症专家合作准备临床试验。计划使用的治疗方法将使用每位患者的 T 细胞,这些细胞将被基因修饰成为 B-SYNC CAR-T 细胞。
从实验室研究过渡到临床测试进展相对迅速,这反映了动物实验中令人鼓舞的发现。
首次试验将由 UCSF 医生 Marie Jaeger-Krause(MD)和 Sabine Mueller(MD, PhD)领导。研究人员计划评估不同静脉给药和直接脑内给药的组合。
对于接受 ICV 治疗的患者,外科医生将植入一根分流管,将大脑室连接到位于头皮下方的储存器。该系统将允许医生在无需每次手术都进行新的手术的情况下给患者重复注射工程免疫细胞。
尽管该治疗方法尚未在人体中测试其有效性,但其在小鼠中完全消除肿瘤并防止其复发的能力已经产生了极大的乐观情绪。
"弥漫性中线胶质瘤对患者及其家庭来说是一个令人心碎的诊断," Mueller 说,她是 UCSF 儿童脑肿瘤中心的主任,UCSF 神经病学、神经外科和儿科教授,以及儿童神经肿瘤学联盟(PNOC)的联合创始人。"这些预临床数据非常有希望。患有 DMG 的小鼠被治愈了,我们非常兴奋能够将这种疗法带给我们关心的儿童和年轻人。这正是他们应得的创新方法。"
来源:ScienceDaily Health & Medicine · sciencedaily.com